Pfizer Inc. raised its full-year earnings projections as the company reported a better-than-expected first-quarter performance, primarily from sales in its biopharmaceutical business. Pfizer raised its adjusted-earnings guidance by 1 cent to $2.83 to $2.93, reflecting operational improvements and better-than-expected earnings in the first quarter.

Source: Wall Street Journal April 30, 2019 11:48 UTC